Bruker Spatial Biology, Inc.

Bruker Spatial Biology, Inc., a for-profit manufacturer of advanced scientific instrumentation based in Billerica, Massachusetts, operates as a prime contractor delivering spatial transcriptomics platforms, molecular genomics reagents, and maintenance services to federal research agencies on a full-and-open basis, with no set-aside designations across its recent award footprint.

Bruker Spatial Biology is a subsidiary of Bruker Nano, Inc. The company specializes in NanoString nCounter systems, Bruker GeoMx Digital Spatial Profiler technologies, and associated reagent kits (code sets, library preparation materials, master kits, and consumables) for spatial gene expression analysis. Its federal work centers on supplying these instruments and reagents directly to research laboratories, providing annual preventive maintenance and on-site technical support, and delivering specialized biological materials for spatial transcriptomics, molecular genomics, liver cancer research, infectious disease investigation, and environmental health science studies. Representative prime work includes a $170.5 thousand five-year maintenance contract with the National Cancer Institute (awarded March 2025, running through March 2030) for GeoMx Digital Spatial Profiler preventive maintenance and data analysis software support at the Tumor Immune-Micro-Environment laboratory; a $107.5 thousand device service plan with the U.S. Department of Agriculture's Agricultural Research Service (awarded September 2025, running through August 2030) for preventive maintenance and repair on two NanoString nCounter Pro units at the National Bio and Agro-Defense Facility in Kansas; and a $129.9 thousand novation agreement with the Department of Veterans Affairs, Veterans Integrated Service Network 17 (awarded April 2023, completion April 2027) for NanoString nCounter maintenance services in Big Spring, Texas.

Bruker Spatial Biology's customer base concentrates heavily within the National Institutes of Health. Across 36 recent awards, 13 distinct federal agencies appear, but the National Cancer Institute (9 awards, $496 thousand combined potential value) and the National Institute of Environmental Health Sciences (9 awards, $184 thousand combined potential value) account for 50% of award count. The National Heart, Lung, and Blood Institute, National Institute of Allergy and Infectious Diseases, and National Institute on Alcohol Abuse and Alcoholism each hold 3 awards. Outside NIH, the Department of Veterans Affairs (multiple Integrated Service Networks) and the Department of Agriculture represent secondary customer concentration. The Office of Logistics and Acquisition Operations' $10 million Blanket Purchase Agreement (awarded October 2024, expiring December 2025) anchors the vendor's vehicle posture and accounts for approximately 88% of combined potential value across all recent awards. Task orders issued under this single-award BPA total 14 orders valued at $281 thousand combined, with individual task order values ranging from $11,645 to $24,763 per order across NIH institutes and component agencies.

Award activity grew sharply: one award in 2023 to twelve in 2024 and twenty in 2025, with two awards recorded in 2026. Four awards (combined potential value $356 thousand) complete within the next twenty-four months and therefore face recompete exposure. NAICS concentration reflects the vendor's product and service posture: nineteen awards carry Biological Product (except Diagnostic) Manufacturing, twelve carry Electronic and Precision Equipment Repair and Maintenance, and three carry Analytical Laboratory Instrument Manufacturing. PSC coding splits evenly between Drugs and Biologicals (15 awards) and Maintenance/Repair/Rebuild of Equipment—Instruments and Laboratory Equipment (15 awards). The vendor obligated $1.1 million against $11.4 million in combined potential value across all recent awards, indicating the majority of awarded ceiling values remain to be drawn. Combined obligated dollars represent approximately 10% of potential value, consistent with early-performance-phase or maintenance-agreement vehicles where annual or periodic invoicing against multi-year ceilings remains nominal until consumption accelerates.